-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3908 Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Research, Patient-reported outcomes, Measurable Residual Disease
Monday, December 9, 2024, 6:00 PM-8:00 PM

Linda Beneforti1,2*, Paul Milne3*, Aurora Chinnici1,2*, Maria Luisa Coniglio1*, Sébastien Héritier4*, Astrid Van Halteren5,6*, Caroline Hutter7*, Irene Trambusti1*, Francesco Pegoraro8,9*, Zofia Hélias-Rodzewicz4*, Raphaela Schwentner7*, Natasja Roozeboom10*, Michele Tanturli11*, Jean-Francois Emile12*, Cor Van Den Bos6*, Milen Minkov7*, Jean Donadieu4, Matthew Collin, MD, PhD3 and Elena Sieni, MD13*

1Pediatric Hematology Oncology, Meyer Children’s Hospital IRCCS, Florence, Italy
2Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy
3Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom
4French Reference Center for Histiocytosis, Department of Pediatric Hematology and Oncology, Trousseau Hospital, AP-HP, Sorbonne Université, Paris, France
5Erasmus University Medical Center, Rotterdam, Netherlands
6Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
7LCH Study group, CCRI, St. Anna Kinderkrebsforschung, Vienna, Austria
8Department of Health Sciences, University of Florence, Florence, Italy
9Department of Hematology and Oncology, Meyer Children’s Hospital IRCCS, Florence, Italy
10Sanquin, Amsterdam, Netherlands
11Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
12Paris-Saclay University, Versailles SQY University, EA4340-BECCOH, Versailles, France
13Meyer Children's Hospital, Florence, Italy

Background: Langerhans cell histiocytosis (LCH) is a rare hematological neoplasia of myeloid origin driven by activating mutations in the mitogen-activated protein kinase pathway, most commonly BRAFV600E. The clinical presentation is heterogeneous ranging from single-system (SS) to multi-system (MS) disease, with or without involvement of risk organs (RO), i.e. liver, spleen, bone marrow. Circulating cell free (ccf-) BRAFV600E has been proposed as a prognostic marker, however molecular-based risk stratification is still an unmet need in patients with LCH.

Purpose: To assess the prognostic significance of BRAFV600E in different sources of peripheral blood at baseline (before therapy) and at 6 weeks of treatment according to LCH-IV in children with BRAF-mutated LCH.

Methods: Peripheral BRAFV600E was measured in five laboratories of the European Consortium for Histiocytosis (Florence-IT, Newcastle-UK, Paris-FR, Amsterdam-NL, Vienna-AU). DNA from circulating-cell-free (ccf, n=307), peripheral blood mononuclear cells (PBMC, n=186), total leukocytes (n=21) or whole blood (n=36) was screened by digital droplet or allele-specific PCR. BRAFV600E levels at baseline and at week 6, in all sources, were correlated to clinical outcome, defined as event (reactivation/treatment intensification) using Mann-Whitney U test. Survival proportions were calculated using the Kaplan-Meier method and Log-rank (Mantel-Cox) test was used to calculate the significance of the difference between survival curves. Pearson correlation coefficient was used to measure the strength of linear associations between ccf and PBMC BRAFV600E.

Results: A total of 259 patients were enrolled. Median age was 29 (IQR=13-79) months; disease extension was represented by 49% SS, 27% MS-RO- and 24% MS-RO+. Data at baseline and week 6 of 259 and 121 patients, respectively, were analyzed. At baseline, BRAFV600E levels were highly correlated between ccf and PBMC-DNA in MS-RO- (r=0.97) and MS-RO+ (r=0.87) but less so in single-system (SS) patients (r=0.53).

At baseline, higher BRAFV600E levels were detected in ccf- versus PBMC-DNA (median 0.093% vs 0.006%, p=0.0003). BRAFV600E levels were significantly associated with disease stage, with a median of 0% in SS, 0.11% in MS-RO-, 1.69% in MS RO+, in ccf-DNA (p<0.0001); 0% in SS, 0.01% in MS RO-, 0.5% in MS RO+, in PBMC-DNA (p<0.0001).

Higher BRAFV600E levels were observed among patients undergoing events within two years, with a median of 0.07% vs 0% in SS (p=0.004), 0.39% vs 0.014% in MS-RO- (p=0.0007), 2.1% vs 0.36% in MS RO+ (p=0.04), in ccf-DNA and 0.006% vs 0% in SS (p=0.003), 0.07% vs 0.002% in MS RO- (p=0.0002), 0.70% vs 0.05% in MS RO+ (p=0.82), in PBMC-DNA, respectively.

In all risk groups, it was possible to define a threshold of BRAFV600E positivity that was associated with shorter 2-year event free survival (EFS). Survival analysis showed significant differences among patients on the basis of the selected cut-offs. At baseline, we identified for ccf-DNA a threshold of 0.1% in SS (p=0.0007) and MS RO- (p=0.0004) patients; 1% in MS RO+ patients (p=0.0182); for PBMC, we established a threshold of 0.01% in SS (p=0.0099) and MS RO- (p<0.0001) patients; 1% in MS RO+ patients (p=0.1414). At week 6, longer 2-year EFS was associated with reduction of >50% of ccf-BRAFV600E (p=0.0002) and clearance of PBMC-BRAFV600E (p=0.059).

Conclusion: Measurement of BRAFV600E, in ccf- and PBMC-DNA, both offer potential prognostic value in children with LCH. This multicenter international study provides the basis for molecular-based risk stratification at baseline and at early time points of treatment in different disease groups. Incorporation of this approach in next prospective therapeutical trials may confirm its role in guiding treatment decisions.

Disclosures: Emile: Deciphera: Honoraria; Servier: Honoraria; Recordati: Honoraria; Oseus: Honoraria.

*signifies non-member of ASH